Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Astrocyte Pharmaceuticals secures $9.5 million in Series B funding to advance Phase 2 clinical development of its breakthrough TBI and concussion therapy AST-004.
Amount Raised
$9.5 Million
Round Type
Series B
Description
Astrocyte Pharmaceuticals has successfully secured $9.5 million in a Series B funding round. The capital will be utilized to advance the Phase 2 clinical development of its innovative therapy for TBI and concussion, named AST-004. This funding will enable the company to conduct crucial trials and further validate its therapeutic approach. The investment underscores the potential impact of AST-004 in addressing significant unmet medical needs in brain injury treatment.
Fundz sees it the moment Astrocyte Pharmaceuticals Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAstrocyte Pharmaceuticals Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.